Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Disrupting monocytic AML and monocytic leukemia stem cells with a novel cladribine regimen: From bench to bedside

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJia HuJHJingyi HuangWZWeiyan Zheng

Discussion

Loading...

Member takes

Overview

Clinical trial demonstrates the CHA regimen's efficacy against therapeutic resistance in leukemia stem cells driven by monocytic AML.

Key Points

  • To evaluate a novel cladribine-based regimen targeting monocytic leukemia stem cells and AML.
  • Proposed a triple-drug regimen including Cladribine, Homoharringtonine, and Cytarabine.
  • Compared the efficacy of CHA regimen to venetoclax/azacitidine in vitro and in xenograft models.
  • Involved enrollment of Asian Chinese patients with newly diagnosed AML for a clinical trial.
  • CHA demonstrated a high complete response rate of 76.2% in the mono-AML subgroup.
  • Ven/Aza showed lower response rates in the mono subgroup compared to prim-AML, indicating lineage-specific efficacy.
  • The CHA regimen was well tolerated with a low treatment-related mortality rate of 1.4%.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce3https://doi.org/10.1182/blood-2025-1508
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025 · 1 citations
  2. 2Cladribine (CLAD) + low-dose AraC (LDAC) + venetoclax (VEN) in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome: Real-world analysis from a large community-based oncology practice.2026
  3. 3Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A2024 · 3 citations
  4. 4Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis2025 · 2 citations
  5. 5Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia2025